The Other Side of the Needle

Earlier in this series, there was a chapter about the bull side of the obesity-drug boom — about Eli Lilly, the company winning the GLP-1 gold rush, and the dangers of paying up for even a genuinely revolutionary growth story. This is the chapter about the other side: about Novo Nordisk, the company that started the gold rush and is now being buried by it, and about what its collapse teaches that no triumphant story can. Because the most valuable lessons in markets are usually written not by the winners but by the fallen leaders — the companies that had everything, that were right about the science, that occupied the very center of the most exciting trend of their era, and that lost their shareholders staggering sums anyway. Novo Nordisk is the purest such lesson the current market has produced, and it deserves to close this collection, because it contains, in a single story, the thread that runs through every other.

Let us be clear about how far it has fallen, because the scale is the whole point. In the middle of 2024, Novo Nordisk — the Danish maker of Ozempic and Wegovy, the semaglutide drugs that had turned weight loss into a pharmaceutical phenomenon — was the most valuable company in Europe, with a market capitalization that peaked around $650 billion, its shares having soared past 1,000 Danish kroner. It was, for a moment, one of the great success stories on earth: a century-old insulin maker transformed into the indispensable supplier of the drugs everyone wanted, its growth seemingly unstoppable, its stock a one-way bet. And then it broke. By 2026 the shares had fallen roughly 70% from that peak — trading in the high $30s as an American depositary receipt, near 52-week lows — erasing nearly all of the enormous market-cap gains it had accumulated since Wegovy's approval, in what was, by 2025, the worst year in the company's history. More than two-thirds of the value of what had been Europe's most valuable company, gone, in roughly two years, while the underlying product remained one of the most sought-after medicines in the world. Hold those two facts together, because their coexistence is the entire lesson: the drug never stopped being a marvel, and the stock lost more than two-thirds of its value anyway.

How the leader lost the race

The first thing the collapse teaches is what happens to second place in a duopoly when the gap turns into a gulf. The obesity-drug market became, in effect, a two-horse race between Novo's semaglutide (Ozempic, Wegovy) and Eli Lilly's tirzepatide (Mounjaro, Zepbound), and for a while both horses ran together, the market so large and growing so fast that there seemed room for both to win enormously. But duopolies are unstable when one product is simply better, and Lilly's tirzepatide proved, in trial after trial and in the real world, to deliver more weight loss. The market noticed. By late 2025, Lilly held something like 63% of U.S. branded anti-obesity prescriptions and a clear majority of total GLP-1 scripts, and its tirzepatide drugs had overtaken Novo's Wegovy and Ozempic in sales — a stunning reversal for the company that had invented the category. Lilly pulled ahead not on one axis but on all of them at once: efficacy, pipeline breadth, manufacturing capacity, oral convenience, and patent duration. The pioneer was being lapped by the fast follower, in its own race.

And then came the moment that turned a competitive setback into something closer to a strategic defeat: CagriSema. This was Novo's great next-generation hope, the drug meant to leapfrog Lilly and restore Novo's lead — and when its trial results came in, they disappointed, failing to deliver the decisive superiority over Lilly's tirzepatide that the bull case required. The stock fell sharply on the news, and analysts began openly doubting the drug's commercial potential. The significance was not just one failed trial; it was the closing of the most visible path back. A company that has lost its lead can recover if its next product reclaims it; CagriSema was supposed to be that product, and when it stumbled, the market was forced to confront the possibility that Novo would not regain the top spot — that the leadership had passed, perhaps permanently, to its rival. Being second in a two-drug market, with your comeback drug having just disappointed, is a far worse place to stand than the $650-billion valuation had ever contemplated.

The price that could only fall

The second lesson is about what happens to the economics of a blockbuster drug as its temporary monopoly ends — and it is a lesson the high valuation had completely failed to price. The extraordinary profitability of Ozempic and Wegovy rested on a simple foundation: patent-protected drugs, in overwhelming demand, sold at very high prices (on the order of a thousand dollars a month in the U.S.) with little competition to undercut them. Every part of that foundation is now crumbling. Semaglutide's patent protection is approaching expiry, which means low-cost generic versions are coming. Compounding pharmacies have already been selling cheaper knockoff versions of semaglutide, forcing Novo into a legal war — it filed a landmark patent-infringement suit against the telehealth company Hims & Hers in February 2026, amid an FDA crackdown on compounding. And the pricing itself is collapsing: Novo cut prices on Wegovy and Ozempic by as much as 48% in India, and announced that, effective January 2027, it would lower the U.S. list price of Wegovy and Ozempic to $675 — reductions of roughly 50% and 35% respectively. A drug whose monthly price is being halved, with generics on the horizon and competitors undercutting it, is a drug whose golden economics are ending.

This is the part the peak valuation most catastrophically misjudged, and it is a recurring error in pharmaceutical investing. At $650 billion, the market was capitalizing Novo's blockbuster profits as if the high-price, high-margin, low-competition moment would persist far into the future. But that moment is, by the very nature of patented pharmaceuticals, always temporary — it lasts exactly as long as the patent and the absence of a better competitor, and not one day longer. The patent cliff is not a surprise risk; it is a contractual certainty, written into the drug from the moment of its approval, with a known expiry date. The arrival of a superior competitor is not a freak event; it is the predictable result of an enormous, lucrative market attracting the best-funded rivals in the industry. The price war is not an aberration; it is what happens to every blockbuster as its exclusivity wanes. Novo's valuation at the peak required all of these normal, foreseeable, structural features of the drug business to somehow not apply — and they applied, all at once, on roughly the schedule a sober analyst could have sketched in advance.

We have watched this cliff before

The most striking thing about Novo's fall is how unoriginal it is — and that unoriginality is itself the warning, because the pharmaceutical industry has run this exact experiment many times and the market keeps forgetting the result. The history of drug stocks is, in large part, a history of patent cliffs: a company develops a blockbuster, the drug's exclusivity creates years of enormous, high-margin profits, the market extrapolates those profits forward and bids the stock to a rich valuation, and then the patent expires (or a superior competitor arrives), generics or rivals flood in, the price and volume collapse, and the profits that justified the valuation evaporate on a schedule that was knowable from the start. Pfizer lived it with Lipitor, the best-selling drug in history, whose patent expiry erased a vast revenue stream. The pattern repeats across the industry with grim regularity, because the structure of the patented-drug business guarantees it: exclusivity is finite, and the cash flows it produces are therefore finite too, however permanent they feel at the peak.

What makes the pattern so durable is a psychological quirk the market commits over and over: at the height of a blockbuster's success, when the drug is dominant and the profits are gushing, the patent cliff feels distant and abstract, easy to discount to nothing, while the current torrent of cash feels concrete and permanent. So the market pays a price that implicitly assumes the torrent never ends — even though the end date is, quite literally, a matter of public record in the patent filings. Novo's investors at $650 billion were making precisely this error in real time: capitalizing the peak-exclusivity profits of semaglutide as if patents did not expire and better drugs did not get invented, in an industry whose entire history screams that both things happen on a predictable schedule. The cliff was always there. It was on the calendar. The valuation simply chose not to look at the date.

The day the music stopped

It is worth marking how fast the reckoning arrived once it began, because the speed is characteristic of what happens when a peak valuation meets reality. For a long while the warning signs accumulated quietly beneath a still-rising or still-elevated stock — the competitive data favoring Lilly, the looming patent questions, the compounding-pharmacy undercutting. Then the dam broke in a series of brutal single-day moves. The CagriSema trial disappointment knocked the stock down sharply in one session. The February 2026 guidance — in which management laid out the case for declining sales and profit in 2026, citing "unprecedented pricing pressure" — sent the shares down on the order of 17 to 20% in a day. Each shock stripped away another layer of the premium that years of optimism had built, and the cumulative effect was the loss of more than two-thirds of the company's value, much of it concentrated in a handful of these violent repricings.

This is how richly-valued stocks tend to fall: not in a smooth, gentle glide that gives holders time to step aside, but in sudden lurches as each new piece of bad news forces an abrupt re-rating, because the high valuation had left no margin to absorb disappointment. A stock priced for perpetual dominance does not decline politely when the dominance is questioned; it gaps down, repeatedly, as the market hurriedly marks the price to a future it had refused to contemplate. Novo's investors did not get a calm exit. They got a sequence of mornings on which the stock was suddenly, sharply worth less than it had been the night before — the characteristic rhythm of a peak unwinding, and a preview of how any of the richly-priced names elsewhere in this series might one day trade when their own assumed perfection is finally tested.

The governance that follows the rout

The third lesson is one this series has noted before: that fundamental collapse and management turmoil tend to arrive together, each amplifying the other. As the business deteriorated, Novo's leadership was upended. The company pushed out its chief executive and installed its first non-Danish CEO, Maziar Mike Doustdar; it brought back a former CEO, Lars Rebien Sørensen, as chairman in a move described as an unprecedented consolidation of power; and other top executives headed for the exits. The new chief executive's own message to investors was bracingly grim: that things would "get worse before they get better." Management churn at the top of a company in crisis is rarely a solution and often a symptom — a sign that the board has lost confidence, that the strategy has failed, that the people who presided over the peak are being held to account for the trough. It also injects fresh uncertainty at exactly the moment the business can least afford it, as a new team takes time to find its footing while the competitive and pricing pressures compound. The boardroom upheaval did not cause Novo's problems, but it confirmed their severity, and it is the kind of disorder that tends to accompany the bottom of a fundamental decline rather than the top.

The value-trap question

So the natural question, after a 70% crash, is the one value investors always ask: is it now cheap? Has the stock fallen so far that the bad news is more than priced in, making Novo a generational bargain rather than a falling knife? The bull case is real and deserves a hearing. Obesity is one of the largest health problems in the world, the total market for GLP-1 drugs is still enormous and growing, Novo remains one of only two companies with the manufacturing scale and expertise to serve it, and it has a genuine bright spot in its oral semaglutide — the Wegovy pill, which removes the needle entirely and which has seen rapid early uptake, with well over a hundred thousand people starting it within weeks of launch. A company trading at a fraction of its former value, still deeply profitable, with a huge market and a promising oral franchise, is not obviously a bad bet, and some serious investors have argued the crash is an overreaction.

But "cheap" is a dangerous word when the fundamentals are still deteriorating, and the bear case is that Novo is not a bargain but a value trap — a stock that looks inexpensive relative to its past but is fairly or even richly priced relative to its future, because that future involves shrinking sales (guidance for 2026 has both revenue and operating profit declining by as much as 13%), collapsing prices, generic competition, and a rival that keeps extending its lead. A low price is only a bargain if the business stabilizes; if sales and margins keep falling, today's "cheap" multiple is sitting on top of earnings that are still on their way down, and the stock can keep declining even from levels that look like value. The honest answer is that no one yet knows whether the oral pill and the still-vast market will stabilize Novo, or whether the price war and the competitive rout will grind it lower; what is clear is that the question is genuinely open, which is itself a long way from the certainty the $650-billion peak had radiated.

The lesson the needle teaches

Step back from the specifics, and Novo Nordisk delivers, more cleanly than any other story in this collection, the single lesson that unites them all. The GLP-1 drugs are real. They are not a mania, not a fraud, not a narrative floating free of substance; they are a genuine medical breakthrough that is improving and extending millions of lives and reshaping the treatment of one of humanity's most stubborn diseases. The science was right. Novo was right to pursue it, right to be at the center of it, right that it would be one of the most important pharmaceutical developments of the century. And its shareholders, buying that rightness at $650 billion, lost more than two-thirds of their money. The product succeeded and the stock failed, at the same time, for the same underlying reason: the price paid had extrapolated a temporary, peak-of-the-cycle condition — monopoly pricing, total dominance, no effective competition — into a permanent future, exactly when the patent cliff, the superior rival, and the price war were already visible on the horizon for anyone willing to look past the excitement.

This is the thread through every chapter here, from the AI chips to the trillion-dollar IPOs to the crypto treasuries to the empty offices: that being right about the technology and right about the price are entirely different problems, and that the manic phase of a cycle is defined precisely by the market's refusal to tell them apart. A revolutionary product is not a license to overpay for the company that makes it. A genuine breakthrough does not suspend the ordinary laws of competition, patents, and pricing. And the most dangerous stocks of all are often not the obvious frauds but the genuine wonders bought at prices that assume the wonder will never be competed away — because the story is true, which makes the overpayment feel safe, right up until the structural realities the price ignored arrive on schedule and take more than two-thirds of the value with them. The needle has two sides. One side delivered a miracle of medicine and a fortune in growth. The other side delivered the patent cliff, the better competitor, the price war, and the 70% decline. They were always the same needle. The market, at the peak, was only willing to look at one side of it. The lesson of Novo Nordisk — and of every story in this collection — is that you must always, always look at both.